These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 33039388)

  • 1. Metabolomics in renal cell carcinoma: From biomarker identification to pathomechanism insights.
    Chen YY; Hu HH; Wang YN; Liu JR; Liu HJ; Liu JL; Zhao YY
    Arch Biochem Biophys; 2020 Nov; 695():108623. PubMed ID: 33039388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of global metabolomics in association with diagnosis and clinicopathological factors of renal cell carcinoma.
    Sato T; Kawasaki Y; Maekawa M; Takasaki S; Saigusa D; Ota H; Shimada S; Yamashita S; Mitsuzuka K; Yamaguchi H; Ito A; Kinoshita K; Koshiba S; Mano N; Arai Y
    Int J Cancer; 2019 Jul; 145(2):484-493. PubMed ID: 30628065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomics informs common patterns of molecular dysfunction across histologies of renal cell carcinoma.
    DiNatale RG; Sanchez A; Hakimi AA; Reznik E
    Urol Oncol; 2020 Oct; 38(10):755-762. PubMed ID: 31155438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of metabolomics-derived biomarkers to identify renal cell carcinoma: a comprehensive perspective of the past ten years and advancements.
    Gupta A; Nath K; Bansal N; Kumar M
    Expert Rev Mol Diagn; 2020 Jan; 20(1):5-18. PubMed ID: 31825678
    [No Abstract]   [Full Text] [Related]  

  • 5. Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems.
    Rodrigues D; Monteiro M; Jerónimo C; Henrique R; Belo L; Bastos ML; Guedes de Pinho P; Carvalho M
    Transl Res; 2017 Feb; 180():1-11. PubMed ID: 27546593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma.
    Zhang M; Liu X; Liu X; Li H; Sun W; Zhang Y
    Int Urol Nephrol; 2020 Mar; 52(3):437-446. PubMed ID: 31732842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urine metabolomics analysis for kidney cancer detection and biomarker discovery.
    Kim K; Aronov P; Zakharkin SO; Anderson D; Perroud B; Thompson IM; Weiss RH
    Mol Cell Proteomics; 2009 Mar; 8(3):558-70. PubMed ID: 19008263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renal cell carcinoma and proteomics.
    Sandim V; Pereira DA; Ornellas AA; Alves G
    Urol Int; 2010; 84(4):373-7. PubMed ID: 20224258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolomic study of human tissue and urine in clear cell renal carcinoma by LC-HRMS and PLS-DA.
    Nizioł J; Bonifay V; Ossoliński K; Ossoliński T; Ossolińska A; Sunner J; Beech I; Arendowski A; Ruman T
    Anal Bioanal Chem; 2018 Jun; 410(16):3859-3869. PubMed ID: 29658093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioinformatic identification of renal cell carcinoma microenvironment-associated biomarkers with therapeutic and prognostic value.
    Zeng Q; Zhang W; Li X; Lai J; Li Z
    Life Sci; 2020 Feb; 243():117273. PubMed ID: 31926244
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis.
    Ganti S; Taylor SL; Abu Aboud O; Yang J; Evans C; Osier MV; Alexander DC; Kim K; Weiss RH
    Cancer Res; 2012 Jul; 72(14):3471-9. PubMed ID: 22628425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular biology of renal cell cancer and the identification of therapeutic targets.
    Iliopoulos O
    J Clin Oncol; 2006 Dec; 24(35):5593-600. PubMed ID: 17158545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolomics and Metabolic Reprogramming in Kidney Cancer.
    Weiss RH
    Semin Nephrol; 2018 Mar; 38(2):175-182. PubMed ID: 29602399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolomic insights into pathophysiological mechanisms and biomarker discovery in clear cell renal cell carcinoma.
    Lucarelli G; Loizzo D; Franzin R; Battaglia S; Ferro M; Cantiello F; Castellano G; Bettocchi C; Ditonno P; Battaglia M
    Expert Rev Mol Diagn; 2019 May; 19(5):397-407. PubMed ID: 30983433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular subtypes and prognosis in RCC.
    Beuselinck B; Fridman WH; Zucman-Rossi J
    Aging (Albany NY); 2015 Apr; 7(4):219-20. PubMed ID: 25885644
    [No Abstract]   [Full Text] [Related]  

  • 17. Acquired Cystic Disease-Associated Renal Cell Carcinoma: Review of Pathogenesis, Morphology, Ancillary Tests, and Clinical Features.
    Foshat M; Eyzaguirre E
    Arch Pathol Lab Med; 2017 Apr; 141(4):600-606. PubMed ID: 28353376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A river model to map convergent cancer evolution and guide therapy in RCC.
    Wei EY; Hsieh JJ
    Nat Rev Urol; 2015 Dec; 12(12):706-12. PubMed ID: 26526752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exosomes in Renal Cell Cancer: Diagnostic and Therapeutic Nanovehicles.
    Boussios S; Ovsepian SV
    Technol Cancer Res Treat; 2024; 23():15330338241275403. PubMed ID: 39149973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic profiling reveals key metabolic features of renal cell carcinoma.
    Catchpole G; Platzer A; Weikert C; Kempkensteffen C; Johannsen M; Krause H; Jung K; Miller K; Willmitzer L; Selbig J; Weikert S
    J Cell Mol Med; 2011 Jan; 15(1):109-18. PubMed ID: 19845817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.